Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.42
- Piotroski Score 4.00
- Grade Neutral
- Symbol (CERT)
- Company Certara, Inc.
- Price $11.01
- Changes Percentage (0.87%)
- Change $0.1
- Day Low $10.08
- Day High $11.02
- Year High $19.87
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $18.00
- High Stock Price Target $28.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.39
- Trailing P/E Ratio -43.54
- Forward P/E Ratio -43.54
- P/E Growth -43.54
- Net Income $-55,357,000
Income Statement
Quarterly
Annual
Latest News of CERT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tech Giants Face a Familiar Uncertainty With Trump
During the first Trump administration, Cecilia Kang and David McCabe covered tech policy from Washington. Trump's unpredictable treatment of the tech industry included antitrust charges, accusations o...
By The New York Times | 22 hours ago -
Federal Reserve is set to cut interest rates again as post-election uncertainty grows
Federal Reserve is expected to lower interest rates due to declining inflation. Trump's presidency adds uncertainty to Fed's future moves, with potential economic impacts like inflation and tariffs in...
By Yahoo! Finance | 1 day ago -
Certara Inc (CERT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Certara Cloud and commercial strategies streamline customer interactions by reducing IT costs, simplifying discussions, aiding software bookings, and easing product implementation. The growth is fuele...
By Yahoo! Finance | 1 day ago
